Dapagliflozin

Healio and Cardiology Today present a list of the most-read articles related to HF and transplantation published in 2019. Readers were most interested in new data that show benefit of SGLT2 inhibition in patients with HF, even in the absence of diabetes; sacubitril/valsartan for HF with preserved ejection fraction, sex-specific prevention and more.

The American Heart Association Scientific Sessions had several presentations with major implications for cardiology, most notably the ISCHEMIA and ISCHEMIA-CKD trials, considered to be the most important findings for management of stable ischemic heart disease in more than a decade.

AstraZeneca announced that the SGLT2 inhibitor dapagliflozin has been granted priority review from the FDA to reduce the risk for CV mortality or worsening HF in patients with HF with reduced ejection fraction with and without type 2 diabetes.

LOS ANGELES — In a presentation at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease, speakers highlighted recent data from the TIMI Study Group on treatment options for diabetes and CVD.

LOS ANGELES — In this video exclusive, Robert P. Giugliano, MD, SM, FACC, FAHA, clinical cardiologist at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, presents an overview of recent trials from the Thrombolysis in Myocardial Infarction (TIMI) Study Group that advance the understanding of new therapies for diabetes, cardiovascular disease and beyond.

Healio and Cardiology Today have compiled a list of the most-viewed cardiology articles in November. This month, our readers were most interested in highlights from the American Heart Association Scientific Sessions including COLCOT and ISCHMIA, the impact of vitamin D and fish oil on HF hospitalization risk, a commentary on the decline of cardiology fellows pursuing electrophysiology training and more.

PHILADELPHIA — In this video exclusive, Robert H. Eckel, MD, professor emeritus of medicine in the division of endocrinology, metabolism and diabetes at the University Colorado, past president of the American Heart Association and president-elect of the American Diabetes Association, discusses several highlights from the AHA Scientific Sessions.

PHILADELPHIA — Treatment with the SGLT2 inhibitor dapagliflozin reduced risk for CV death and worsening HF across a broad spectrum of age, independent of symptomatic impairment at baseline, according to two new post-hoc analyses of the DAPA-HF trial presented at the American Heart Association Scientific Sessions.

Healio and Cardiology Today compiled a list of the most-viewed cardiology posts in September. This month, our readers were interested in recalls of losartan due to impurities, the DAPA-HF and DEFINE-HF studies showing benefit of dapagliflozin (Farxiga, AstraZeneca) in patients with HF regardless of diabetes status, the effect of a salt substitution regimen on hypertension and much more.

The diabetes drug dapagliflozin has been approved by the FDA to reduce the risk for heart failure hospitalization among adults with type 2 diabetes who also have cardiovascular disease or multiple CV risk factors, according to a press release from AstraZeneca.